ImmuCell Corp (ICCC)
5.42
+0.13
(+2.46%)
USD |
NASDAQ |
May 10, 16:00
5.42
0.00 (0.00%)
After-Hours: 20:00
ImmuCell Research and Development Expense (Quarterly): 1.066M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.066M |
| September 30, 2023 | 1.118M |
| June 30, 2023 | 1.100M |
| March 31, 2023 | 1.110M |
| December 31, 2022 | 1.049M |
| September 30, 2022 | 1.270M |
| June 30, 2022 | 1.139M |
| March 31, 2022 | 1.036M |
| December 31, 2021 | 1.090M |
| September 30, 2021 | 1.048M |
| June 30, 2021 | 1.000M |
| March 31, 2021 | 1.031M |
| December 31, 2020 | 1.170M |
| September 30, 2020 | 1.123M |
| June 30, 2020 | 1.087M |
| March 31, 2020 | 0.9744M |
| December 31, 2019 | 0.9725M |
| September 30, 2019 | 0.9847M |
| June 30, 2019 | 0.8201M |
| March 31, 2019 | 0.9104M |
| December 31, 2018 | 1.263M |
| September 30, 2018 | 0.9088M |
| June 30, 2018 | 0.7619M |
| March 31, 2018 | 0.5829M |
| December 31, 2017 | 0.7341M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.5858M |
| June 30, 2017 | 0.387M |
| March 31, 2017 | 0.3396M |
| December 31, 2016 | 0.2537M |
| September 30, 2016 | 0.3077M |
| June 30, 2016 | 0.3804M |
| March 31, 2016 | 0.3024M |
| December 31, 2015 | 0.3311M |
| September 30, 2015 | 0.3017M |
| June 30, 2015 | 0.2718M |
| March 31, 2015 | 0.3307M |
| December 31, 2014 | 0.463M |
| September 30, 2014 | 0.3612M |
| June 30, 2014 | 0.7607M |
| March 31, 2014 | 0.5942M |
| December 31, 2013 | 0.325M |
| September 30, 2013 | 0.2909M |
| June 30, 2013 | 0.2719M |
| March 31, 2013 | 0.2665M |
| December 31, 2012 | 0.2343M |
| September 30, 2012 | 0.2238M |
| June 30, 2012 | 0.2117M |
| March 31, 2012 | 0.2478M |
| December 31, 2011 | 0.2711M |
| September 30, 2011 | 0.3041M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.8201M
Minimum
Jun 2019
1.270M
Maximum
Sep 2022
1.063M
Average
1.066M
Median
Dec 2023
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |
| Oragenics Inc | 11.04M |